Abstract Library

#4331 Amino acid-induced hyperkalaemia during peptide receptor radionuclide therapy (PRRT): A case report and literature review

Introduction: PRRT an established treatment for neuroendocrine tumours (NETs). Therapy requires prophylactic positively charged amino acid (AA) co-infusion to reduce renal radiation exposure. AA infusion has been associated with metabolic acidosis and electrolyte abnormalities, particularly hyperkalaemia; comprehensive data on the prevalence and severity of these complications remains limited.

Conference:

Presenting Author:

Authors: Osher E, Wolf I, Geva R, Sofer Y, Greenman Y,

Keywords: PRRT, hyperkalaemia, amino acid infusion, neuroendocrine tumour, adverse effects,

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,

#3428 Indocyanine green fluorescence guided resection of neuroendocrine liver metastases: A proof-of-concept study

Introduction: Even though the relative indolent character of neuroendocrine neoplasms, untreated NELM have a detrimental impact on survival outcomes. Therefore, complete resection is recommended if technically possible.

Conference:

Presenting Author: Kaçmaz E

Authors: Kaçmaz E, Slooter M, Tanis P, Nieveen van Dijkum E, Swijnenburg R,

Keywords: neuroendocrine liver metastasis, fluorescence guided surgery, indocyanine green,

#3102 Fluorescence angiography guided resection of small bowel neuroendocrine neoplasms with mesenteric lymph node metastases

Introduction: Surgery for small bowel neuroendocrine neoplasms (SB-NEN) might result in vascular compromise of the remaining bowel due to resection of lymph node metastases in close proximity to main mesenteric vessels. Fluorescence angiography (FA) has been described as a safe technique to assess perfusion during gastro-intestinal surgery.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Kaçmaz E, Slooter M, Nieveen van Dijkum E, Tanis P, Engelsman A,

Keywords: fluorescence angiography, indocyanine green, neuroendocrine neoplasm, small bowel, lymph node metastases,

#2169 Patient and Clinician Perspectives on Symptom Priorities Across the Spectrum of Neuroendocrine Tumors (NETs)

Introduction: NETs are associated with a range of symptoms, and symptom reduction is a common treatment target. Identifying priority symptoms across NETs can help inform clinical trial endpoints.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Kaiser K, Webster K, Shaunfield S, Greene G, Yount S,

Keywords: neuroendocrine tumors, priority symptoms, qualitative methods,